文献速递多重用药衰弱、肌少症与跌倒老年慢病共病管理

射血分数保留心衰患者对处方精简的态度

Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction.
PubMed 文献 · J Am Geriatr Soc · 2021-05-12

本研究回顾性纳入134例在纽约学术医学中心就诊的射血分数保留心衰(HFpEF)老年患者,评估其脆弱性及对处方精简的态度。结果显示94.0%存在多重用药,90.3%愿意在医生建议下精简药物,91.8%希望参与用药决策;非白人患者尝试停药意愿较低(OR 0.25,95%CI 0.09-0.62,p=0.005)。

要点

  • HFpEF患者多重用药普遍(94.0%),超多重用药达56.0%。
  • 90.3%愿意在医生建议下精简一种或以上药物。
  • 非白人患者尝试停药意愿显著低于白人(OR 0.25)。

核心结论

  • 多数HFpEF患者对处方精简持接受态度,但不同种族态度存在差异。

主要发现

  • 134例患者中位年龄75岁(四分位距69-82),60.4%为女性,35.8%为非白人。
  • 94.0%存在多重用药,56.0%为超多重用药;80.6%共病,78.7%衰弱。
  • 90.3%报告若医生告知可能,愿意精简一种或以上药物;26.9%希望尝试停用一种药物以观察感受。
  • 91.8%希望参与用药决策。
  • 双变量逻辑回归显示,非白人参与者尝试停药意愿较低(OR 0.25,95%CI 0.09-0.62,p=0.005)。

关键数值与推荐

  • 采用修订版患者处方精简态度量表(rPATD)评估态度。

临床怎么用

  • 对HFpEF老年患者应常规评估多重用药与脆弱性,并主动沟通处方精简可能性。
  • 用药决策中应尊重患者参与意愿,并关注种族差异对停药态度的影响。

局限性

  • 单中心回顾性研究,样本量有限,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Attitudes toward deprescribing could vary among subpopulations. We sought to understand patient attitudes toward deprescribing among patients with heart failure with preserved ejection fraction (HFpEF). DESIGN: Retrospective cohort study. SETTING: Academic medical center in New York City. PARTICIPANTS: Consecutive patients with HFpEF seen in July 2018-December 2019 at a program dedicated to providing care to older adults with HFpEF. MEASUREMENTS: We assessed the prevalence of vulnerabilities outlined in the domain management approach for caring for patients with heart failure and examined data on patient attitudes toward having their medicines deprescribed via the revised Patient Attitudes Toward Deprescribing (rPATD). RESULTS: Among 134 patients with HFpEF, median age was 75 (interquartile range 69-82), 60.4% were women, and 35.8% were nonwhite. Almost all patients had polypharmacy (94.0%) and 56.0% had hyperpolypharmacy; multimorbidity (80.6%) and frailty (78.7%) were also common. Overall, 90.3% reported that they would be willing to have one or more of their medicines deprescribed if told it was possible by their doctors; and 26.9% reported that they would like to try stopping one of their medicines to see how they feel without it. Notably, 91.8% of patients reported that they would like to be involved in decisions about their medicines. In bivariate logistic regression, nonwhite participants were less likely to want to try stopping one of their medicines to see how they feel without it (odds ratio 0.25, 95% confidence interval [0.09-0.62], p = 0.005). CONCLUSIONS: Patients with HFpEF contend with many vulnerabilities that could prompt consideration for deprescribing. Most patients with HFpEF were amenable to deprescribing. Race may be an important factor that impacts patient attitudes toward deprescribing.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Navid P, Nguyen L, Jaber D, et al. Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction. J Am Geriatr Soc. 2021. PMID: 33978239. doi:10.1111/jgs.17204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。